The DCI Proteomics Shared Resource was designed to provide qualitative and quantitative proteomic support using nanoscale ultraperformance liquid chromatographs (single or multidimensional) coupled to high- resolution accurate-mass tandem mass spectrometers (LC/LC/MS/MS). While the Facility is available for use by the entire Duke research community, DCI members have priority access and are the first invited to participate in the Facility's significant early-access technology development projects. These projects are a direct result of close working relationships between the Proteomics Facility and instrument/software/reagent companies. As just one example, the Proteomics Facility is a formal Center of Innovation for Waters Corporation, the manufacturer of the majority of our LC and MS tools. These industry relationships are integral to the Proteomics Facility's ability to provide affordable emerging technologies to answer innovative research questions relevant to DCI members. The Proteomics Facility utilizes ~$4M of state-of-the-art proteomic instrumentation for basic science experiments and clinical studies (including biomarker discovery and biomarker verification). Facility policy initiates all potential projects with an on-site consultation with PhD-level Facility staff to enable collaborative creation of custom experimental designs that meet the researcher's scientific needs. The Facility uses a custom, state of the art LIMS for secure electronic sample submission and data return. The Facility's operating budget is supported by the Cancer Center Support Grant, the Duke Translational Research Institute (DTRI), and user chargebacks, the last of which accounts for the vast majority of our budget. Our annual cost-effectiveness survey shows that our user fees, which reflect actual costs, are at or lower than other academic proteomics facilities. In calendar year 2012, the Facility served 90 investigators, 27 of whom were DCI members. Use of the Resource contributed to 36 DCI publications during the funding period. The long-term objectives of the Proteomics Core Facility/Shared Resource are (1) to continue to provide the highest quality, cost-effective, full-service proteomics expertise and analyses to the Duke research community, with priority given to DCI members, and (2) to continue testing and, when appropriate, implementing emerging proteomic and mass spectrometry technologies through our relationships with industry partners and with the involvement of DCI researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-44
Application #
9404302
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications